Literature DB >> 9371579

Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo.

D E Brough1, C Hsu, V A Kulesa, G M Lee, L J Cantolupo, A Lizonova, I Kovesdi.   

Abstract

The persistence of transgene expression has become a hallmark for adenovirus vector evaluation in vivo. Although not all therapeutic benefit in gene therapy is reliant on long-term transgene expression, it is assumed that the treatment of chronic diseases will require significant persistence of expression. To understand the mechanisms involved in transgene persistence, a number of adenovirus vectors were evaluated in vivo in different strains of mice. Interestingly, the rate of vector genome clearance was not altered by the complete deletion of early region 4 (E4) in our vectors. The GV11 (E1- E4-) vector genome cleared with a similar kinetic profile as the GV10 (E1-) vector genome in immunocompetent and immunocompromised mice. These results suggest that the majority of adenovirus vector genomes are eliminated from transduced tissue via a mechanism(s) independent of T-cell, B-cell, and NK cell immune mechanisms. While the levels of persistence of transgene expression in liver or lung transduced with GV10 and GV11 vectors expressing beta-galactosidase, cystic fibrosis transmembrane conductance regulator, or secretory alkaline phosphatase were similar in immunocompetent mice, a marked difference was observed in immunocompromised animals. Levels of transgene expression initially from both GV10 and GV11 vectors were the same. However, GV11 transgene expression correlated with loss of vector genome, while GV10 transgene expression persisted at a high level. Coadministration and readministration of GV10 vectors showed that E4 provided in trans could activate transgene expression from the GV11 vector genome. While transgene expression activity per genome from the GV10 vector is clearly activated, expression from a cytomegalovirus promoter expression cassette in a GV11 vector appeared to be further inactivated as a function of time. Understanding the molecular mechanisms underlying these expression effects will be important for developing persistent adenovirus vectors for chronic applications.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9371579      PMCID: PMC230223     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells.

Authors:  J Berger; J Hauber; R Hauber; R Geiger; B R Cullen
Journal:  Gene       Date:  1988-06-15       Impact factor: 3.688

2.  Human adenovirus encodes two proteins which have opposite effects on accumulation of alternatively spliced mRNAs.

Authors:  K Nordqvist; K Ohman; G Akusjärvi
Journal:  Mol Cell Biol       Date:  1994-01       Impact factor: 4.272

3.  Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver.

Authors:  J F Engelhardt; X Ye; B Doranz; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

4.  Mechanism of activation of early viral transcription by the adenovirus E1A gene product.

Authors:  J R Nevins
Journal:  Cell       Date:  1981-10       Impact factor: 41.582

5.  Mutant adenovirus type 9 E4 ORF1 genes define three protein regions required for transformation of CREF cells.

Authors:  R S Weiss; M O Gold; H Vogel; R T Javier
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

6.  Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression.

Authors:  Y Dai; E M Schwarz; D Gu; W W Zhang; N Sarvetnick; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

7.  Adenovirus type 9 E4 open reading frame 1 encodes a transforming protein required for the production of mammary tumors in rats.

Authors:  R T Javier
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

8.  Introduction, stable integration, and controlled expression of a chimeric adenovirus gene whose product is toxic to the recipient human cell.

Authors:  D F Klessig; D E Brough; V Cleghon
Journal:  Mol Cell Biol       Date:  1984-07       Impact factor: 4.272

9.  Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a.

Authors:  J F Engelhardt; L Litzky; J M Wilson
Journal:  Hum Gene Ther       Date:  1994-10       Impact factor: 5.695

10.  Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis.

Authors:  Y Yang; F A Nunes; K Berencsi; E Gönczöl; J F Engelhardt; J M Wilson
Journal:  Nat Genet       Date:  1994-07       Impact factor: 38.330

View more
  21 in total

1.  E4ORF3 requirement for achieving long-term transgene expression from the cytomegalovirus promoter in adenovirus vectors.

Authors:  D Armentano; M P Smith; C C Sookdeo; J Zabner; M A Perricone; J A St George; S C Wadsworth; R J Gregory
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts.

Authors:  C Hidaka; E Milano; P L Leopold; J M Bergelson; N R Hackett; R W Finberg; T J Wickham; I Kovesdi; P Roelvink; R G Crystal
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

3.  Induction of endogenous genes following infection of human endothelial cells with an E1(-) E4(+) adenovirus gene transfer vector.

Authors:  R Ramalingam; S Rafii; S Worgall; N R Hackett; R G Crystal
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

Review 4.  Intratympanic Gene Delivery of Antimicrobial Molecules in Otitis Media.

Authors:  Sung K Moon; David J Lim
Journal:  Curr Allergy Asthma Rep       Date:  2015-04       Impact factor: 4.806

5.  Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes.

Authors:  V Molinier-Frenkel; H Gahery-Segard; M Mehtali; C Le Boulaire; S Ribault; P Boulanger; T Tursz; J G Guillet; F Farace
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

6.  Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons.

Authors:  N Morral; W O'Neal; K Rice; M Leland; J Kaplan; P A Piedra; H Zhou; R J Parks; R Velji; E Aguilar-Córdova; S Wadsworth; F L Graham; S Kochanek; K D Carey; A L Beaudet
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

7.  Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3.

Authors:  M I Gorziglia; C Lapcevich; S Roy; Q Kang; M Kadan; V Wu; P Pechan; M Kaleko
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

8.  Variables affecting in vivo performance of high-capacity adenovirus vectors.

Authors:  Gudrun Schiedner; Sabine Hertel; Marion Johnston; Volker Biermann; Volker Dries; Stefan Kochanek
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

Review 9.  Gene therapy in the inner ear using adenovirus vectors.

Authors:  Jacob Husseman; Yehoash Raphael
Journal:  Adv Otorhinolaryngol       Date:  2009-06-02

10.  Transforming potential of the adenovirus type 5 E4orf3 protein.

Authors:  M Nevels; B Täuber; E Kremmer; T Spruss; H Wolf; T Dobner
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.